Protara Therapeutics Reports TARA-002 Achieves 72% Complet...

TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patients
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events
Company remains on track to initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026

Protara Therapeutics Reports TARA-002 Achieves 72% Complete Response Rate In BCG-Naïve NMIBC Patients With Durable 55% Rate At 12 Months